Patients who will be at this time receiving drugs which have been strong inducers or inhibitors of CYP3A4 aren't suitable. Solid inducers or inhibitors of CYP3A4 need to be prevented from fourteen times previous to enrollment to the top of the review. A.G.H. has obtained study funding from Bayer AG https://carle443rcn6.wikimidpoint.com/user